Abstract:Background: Aspirin is a frequently prescribed drug for primary and secondary prevention of myocardial infarction, stroke and cardiovascular death. However, aspirin resistance may affect up to 45% of the population. Little is known on the role of genetic factors that contribute to resistance or augmented response to aspirin in different human populations. Methods: In a large sample of nonsmoker, medication-free healthy volunteers from mainland China (n = 323; age: 22.1 +/- 2.0 years) (mean standard deviation), we determined the frequency of polymorphisms in cyclooxygenase 1 (COX1) (A-842G and C50T), glycoprotein IIIa (GPIIIa) (PLA1/A2) and purinergic receptor P2Y (P2Y1) (C893T and A1622G) genes. These candidate genes were chosen on the basis of their impact on platelet physiology and aspirin mode of action. A four panel P2Y1 genotype-stratified sample of healthy volunteers (n = 24 in total), identified from the large study sample above, prospectively received a 100 mg daily oral dose of aspirin for 7 days. We measured changes in platelet aggregation before and after aspirin treatment. As a comparison reference group, 6 out of 24 subjects in the prospective aspirin trial had the P2Y1 CT893/AG1622 genotype that displays a low frequency (< 7%) in the Chinese population. Results: COX1 A-842G, C50T and GPIIIa PLAVA2 genetic polymorphisms were not observed in our sample from mainland China. Allele frequencies of P2Y1 893T and 1622G were 3.5 and 30.6%, respectively. The heterozygosity for the P2YI A1622G polymorphism observed in the present study was different to Caucasians; Chinese displayed a higher allele frequency for the 1622G allele. After aspirin treatment, the net decrease in arachiclonic acid-induced platelet aggregation was significantly larger in the P2Y1 CT893/AG1622 genotype panel (83.4 +/- 3.7%, net reduction by aspirin expressed as percentage of baseline) compared with CC893/GG1622 (68.2 +/- 13.5%), CC893/AG1622 (68.9 +/- 9.6%) and CC893/AA1622 (65.1 +/- 9.1 %) genotypic groups (p = 0.012, 0.025 and 0.004, respectively; statistical power = 77%). There was no significant difference in antiplatelet effect of aspirin among the CC893/GG1622, CC893/AG1622 and CC893/AA1622 genotypes (p > 0.05). Conclusions: The COX1 A-842G, C50T and GPIIIa PLAVA2 polymorphisms are rare in Chinese. In contrast to previous studies in Caucasian populations, these candidate functional polymorphisms are unlikely to be significant contributors to aspirin pharmacodynamics in Chinese persons. Importantly, the presence of the P2YI 893CC genotype appears to confer an attenuated antiplatelet effect during aspirin treatment in healthy Chinese volunteers. These data collectively underscore the importance of population-to-population variability in clinical pharmacogenetics research and provide a basis for further long-term studies of aspirin response and P2Y1 genetic variation in patients with cardiovascular risk.

Chronic Application of Low-Dose Aspirin Affects Multiple Parameters of Three Blood Cellular Types and Antithrombin Activity: A 1:1:1 Propensity Score Matching Analysis

Aspirin Resistance in the Elder Cardio-Cerebral-Vascular Diseases Patients

Effect of a single dose aspirin on platelets in humans with multiple risk factors for coronary artery disease

The Effect of Different Dosage of Aspirin on Inflammatory Biomarkers and Prognosis in Acute Coronary Syndrome

Effect of ABO Blood Group Factor on Anticoagulation with Aspirin

Effect of Low-Dose Aspirin on Serum Uric Acid Levels in Chinese Individuals over 60: Subanalysis of a Multicentre Randomized Clinical Trial.

Evaluating the effect of different doses of aspirin on the platelet inhibition rate by thromboelastography

Mir-34B-3p May Promote Antiplatelet Efficiency of Aspirin by Inhibiting Thromboxane Synthase Expression

Anti-aggregation Effect and Short-term Safety Evaluation of Low-dose Aspirin Therapy in the Elderly Chinese Population: a Multicenter Randomized Controlled Clinical Trial

[Aspirin Resistance in Patients Taking Small Dose of Aspirin].

Comparison Between Urinary 11-Dehydrothromboxane B2 Detection and Platelet Light Transmission Aggregometry (lta) Assays for Evaluating Aspirin Response in Elderly Patients with Coronary Artery Disease

Frequency of genetic polymorphisms of COX1, GPIIIa and P2Y1 in a Chinese population and association with attenuated response to aspirin.

Dose-response of Aspirin on Platelet Function in Very Elderly Patients

IDENTIFICATION OF ASPIRIN RESPONSE RELATED GENE PROFILES IN THE ELDERLY POPULATION WITH CORONARY ARTERY DISEASE

Aspirin Response and Related Factors in Aged Patients

Effects of high- and low-dose aspirin on adaptive immunity and hypertension in the stroke-prone spontaneously hypertensive rat

Optical platelet aggregation versus thromboxane metabolites in healthy individuals and patients with stable coronary artery disease after low-dose aspirin administration

ASSA14-03-38 Comparison of Urinary11-DehydrothromboxaneB2 detection and Plasma LTA Assay for evaluating aspirin response in the Aged Patients with Coronary Artery Disease

Abstract MP30: Metabolomics Analyses Identified Factors Modifying the Association of Aspirin Use With Kidney Function

A Laboratory Research of Aspirin Resistance

Platelet Glycoproteins Associated with Aspirin-Treatment Upon Platelet Activation